Papers by Szilvia Szakony
Orvosi Hetilap, Dec 16, 2023
Clinica Chimica Acta, 2019
Nephrology Dialysis Transplantation, 2013
Introduction and Aims: Peginesatide is a once-monthly, peptide-based erythropoiesis-stimulating a... more Introduction and Aims: Peginesatide is a once-monthly, peptide-based erythropoiesis-stimulating agent (ESA) approved in the US for treatment of anemia due to chronic kidney disease (CKD) in adult patients (pts) on dialysis. Peginesatide demonstrated noninferiority to epoetin in maintaining hemoglobin (Hb) in hemodialysis (HD) pts in two Phase 3 randomized trials (EMERALD 1, 2; Fishbane et al. NEJM 2013). Time to dose stability with a less frequently administered ESA is an issue of clinical interest. This post-hoc analysis evaluated the time to achieve initial dose stability in pts who converted from stable epoetin to peginesatide, or maintenance of dose stability in pts who remained on epoetin. Methods: Data were pooled from the EMERALD trials assessing safety and efficacy of peginesatide (Q4W; n=1066) vs epoetin alfa/beta (1-3x weekly; n=542) in HD pts previously on stable epoetin. Dose adjustments were to be made no more than once Q4W (unless for safety reasons) to maintain Hb 10-12 g/dL (per guidelines in effect at time of trial). Hb was measured Q2W (or QW during evaluation period [Wk 29-36] and dose postponements). Due to different dosing frequencies, definitions of dose stability were different between treatments: (1) subsequent dose changed by <20% of prior dose, with 21-35d between doses (peginesatide) or total dose in subsequent month changed by <20% of prior month's total dose (epoetin); and (2) at least 1 Hb was within target between doses (peginesatide) or between first dose of consecutive months (epoetin). The evaluable population were pts who received ≥2 peginesatide doses (n=1034) or ≥2 months of epoetin (n=528). Results: Similar proportions (96.6%) of pts achieved (peginesatide) or maintained (epoetin) dose stability. For peginesatide and epoetin, respectively, dose stability was achieved or maintained after: 1st dose in 61.4% and 54.9%, 2nd dose in 76.7% and 67.4%, and 3rd dose in 84.9% and 77.2% of pts. The most common reason for not achieving peginesatide initial dose stability at 1st dose was a ≥20% decrease in the 2nd dose. Both groups achieved or maintained dose stability at similar rates (in wks; Fig). Conclusions: After conversion from stable epoetin, >75% of peginesatide pts achieved initial dose stability within 1-2 doses. Compared with pts who remained on epoetin, peginesatide pts did not differ in achievement of dose stability. These post-hoc results may warrant further study.
Orvosi Hetilap
A primer szklerotizáló cholangitis (PSC) nőkben különösen ritka, progrediáló, cholestasissal és g... more A primer szklerotizáló cholangitis (PSC) nőkben különösen ritka, progrediáló, cholestasissal és gyakran colitis ulcerosával járó, súlyos formájában szervátültetést igénylő májbetegség. A teherbe esés esélyére és a várandósság kiviselésére gyakorolt hatását hazai közlemény eddig nem elemezte. Közleményünk célja a súlyos colitis ulcerosával és cholestasissal szövődött PSC mellett fogant várandósság lefolyásával foglalkozó irodalom áttekintése, egy fiatal, először várandós sikeres szülése, majd postpartum colectomiája kapcsán. A 37 éves, májátültetésre váró primigravida várandóssága spontán fogant, és súlyos májbetegsége mellett, a gyógyszeresen kezelhető magas vérnyomás ellenére, zavartalan lefolyású volt. A harmadik trimeszterben cholestasisa jelentősen fokozódott, a szérum-összepesavszint 100 μmol/l fölé emelkedett, de napi 8 g kolesztiramin adásával az érték rövid időn belül a normáltartományba csökkent. Késői koraszülése a fekélyes vastagbélgyulladás akut fellángolása következtébe...
Nephrology Dialysis Transplantation, May 1, 2022
The Journal of rheumatology, 2000
To investigate the relationship between antiprothrombin (aPT) and antiannexin V (aANX) autoantibo... more To investigate the relationship between antiprothrombin (aPT) and antiannexin V (aANX) autoantibodies of IgG isotype and thrombosis in patients with systemic autoimmune diseases. To compare the clinical relevance of these antibodies to that of anticardiolipin (aCL), anti-beta2-glycoprotein I antibodies (anti-beta2-GPI), and lupus anticoagulant (LAC). Serum IgG aPT, aANX, aCL, and anti-beta2-GPI levels were measured by solid phase enzyme immunoassay in the sera of 70 patients with systemic autoimmune diseases, 35 with antiphospholipid syndrome (APS) and 35 without APS. Medical records were analyzed, and associations of the antibodies with clinical features of APS were assessed. Patients with APS had higher frequency of aPT (p = 0.001) and aANX (p = 0.002) compared to patients without APS. Thrombotic events occurred more frequently in those with aPT or aANX than those without (p = 0.005, p = 0.006, respectively). The presence of aPT and aANX was found to be highly specific for APS. Me...
Clinical and Experimental Immunology, 1999
SUMMARY The aim of this study was to evaluate the prevalence of IgG, IgA and IgM anti-β2-GPI anti... more SUMMARY The aim of this study was to evaluate the prevalence of IgG, IgA and IgM anti-β2-GPI antibodies in anti-phospholipid syndrome (APS), and to establish the clinical significance of IgA type antibodies compared with the other isotypes. Anti-β2-GPI antibodies were measured in the sera of 70 patients by solid-phase enzyme immunoassay in γ-irradiated polystyrene plates coated with human purified β2-GPI. Thirty-three out of the 70 patients were classified as having APS: three of them had primary, and 30 had secondary APS related to systemic lupus erythematosus (SLE). The remaining 37 patients had SLE without APS. Anti-β2-GPI antibodies of IgG, IgA and IgM isotypes were present in 84.8%, 59.3% and 51.5% of patients with APS. Both the frequency and the level of each isotype were significantly higher in patients with APS. This association was very strong for IgA (P = 0.0004 for the antibody frequency and P < 0.0001 for the antibody level), as well as for IgG type antibodies (P <...
British Journal of Haematology, 1999
et al.; Liver Cancer Study Group of Japan. Significance of the surgical hepatic resection margin ... more et al.; Liver Cancer Study Group of Japan. Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma.
Uploads
Papers by Szilvia Szakony